Re-irradiation for children with diffuse intrinsic pontine glioma and diffuse midline glioma

Shariff N 1 , Moreno AS 2 , Bennett J 3 , Ramaswamy V 3 , Das A 3 , Liu AP 3 Show all authors , Huang A 3 , Tabori U 3 , Hawkins C 4 , Dirks P 5 , Bouffet E 3 , Keilty DM 2 , Millar BA 2 , Hodgson DC 2 , Tsang DS 6

Affiliations 

  • 1 Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Canada; Department of Clinical Oncology, University Malaya Medical Centre, Canada
  • 2 Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Canada
  • 3 Division of Haematology/Oncology, Hospital for Sick Children, Canada
  • 4 Department of Paediatric Laboratory Medicine, Hospital for Sick Children, Canada
  • 5 Division of Neurosurgery, Hospital for Sick Children, Canada
  • 6 Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Canada. Electronic address: derek.tsang@uhn.ca
Radiother Oncol, 2025 Mar 24.
PMID: 40139463 DOI: 10.1016/j.radonc.2025.110865

Abstract

BACKGROUND AND PURPOSE: Diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma (DMG) are incurable brain malignancies. In this study, we report one of the largest known single-institution cohorts of DIPG/DMG patients undergoing re-irradiation (RT2) to evaluate its effect on survival.

MATERIALS AND METHODS: Children aged less than 18 years treated for DIPG/DMG with initial fractionated photon radiotherapy (RT1) and had subsequent recurrence were retrospectively reviewed. Patients treated with or without RT2 were compared. The primary outcomes were overall survival (OS) from time of recurrence after RT1, and from start of RT2 (for the RT2 group).

RESULTS: A total of 118 children were included, 39 of whom received RT2. Children treated with RT2 had superior OS, with 6-month OS of 66 % vs 22 % in those who did not undergo RT2 (p 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications